CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241512317 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Wei Wei und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an 710032, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Young Talent fund of the University Association for Science and Technology in Shaanxi, China.
Abstract (Originalsprache)
As an emerging treatment strategy for malignant tumors, chimeric antigen receptor T (CAR-T) cell therapy has been widely used in clinical practice, and its efficacy has been markedly improved in the past decade. However, the clinical effect of CAR-T therapy is not so satisfying, especially in solid tumors. Even in hematologic malignancies, a proportion of patients eventually relapse after receiving CAR-T cell infusions, owing to the poor expansion and persistence of CAR-T cells. Recently, CRISPR/Cas9 technology has provided an effective approach to promoting the proliferation and persistence of CAR-T cells in the body. This technology has been utilized in CAR-T cells to generate a memory phenotype, reduce exhaustion, and screen new targets to improve the anti-tumor potential. In this review, we aim to describe the major causes limiting the persistence of CAR-T cells in patients and discuss the application of CRISPR/Cas9 in promoting CAR-T cell persistence and its anti-tumor function. Finally, we investigate clinical trials for CRISPR/Cas9-engineered CAR-T cells for the treatment of cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an 710032, China.
Förderung
- the Young Talent fund of the University Association for Science and Technology in Shaanxi, China
Zitieren
APA
Wei, W., Chen, Z. N., & Wang, K. (2023). CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241512317
Vancouver
Wei W, Chen ZN, Wang K. CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241512317
BibTeX
@article{Wei2023,
author = {Wei, Wei and Chen, Zhi-Nan and Wang, Ke},
title = {CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241512317}
}
EUVIMED